COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations

Cancer Causes and Control

Volumn 24, Issue 12, 2013, Pages 2059-2075

  Makar, Karen W ^a   Poole, Elizabeth M ^a,b,c   Resler, Alexa J ^a,e   Seufert, Brenna ^a   Curtin, Karen ^d   Kleinstein, Sarah E ^a,l   Duggan, David ^f   Kulmacz, Richard J ^g   Hsu, Li ^a   Whitton, John ^a   Carlson, Christopher S ^a   Rimorin, Christine F ^a   Caan, Bette J ^h   Baron, John A ^i,j   Potter, John D ^a,e,m   Slattery, Martha L ^d   Ulrich, Cornelia M ^a,e,k  

^a Fred Hutchinson Cancer Research Center   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ DARTMOUTH MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m MASSEY UNIVERSITY   (New Zealand)

more..

Author keywords

Aspirin; Colorectal cancer; COX; Genetic association; NSAID; Polymorphism; PTGS

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN H SYNTHASE 1 GENE; PROSTAGLANDIN H SYNTHASE 2 GENE; RECTUM CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECTAL NEOPLASMS; RISK FACTORS; WASHINGTON;

EID: 84889084275     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0282-1     Document Type: Article

References (55)

1. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130-140
2. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181-193
3. Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31:986-1000
4. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182
5. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188
6. Kutchera W, Jones DA, Matsunami N et al (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 93:4816-4820
7. Hull MA, Fenwick SW, Chapple KS, Scott N, Toogood GJ, Lodge JP (2000) Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 18:21-27
8. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142
9. Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809
10. Patrono C, Patrignani P, Garcia Rodriguez LA (2001) Cyclooxygenase- selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7-13
11. Rothwell PM, Wilson M, Elwin CE et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750
12. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366-1372
13. Pedersen AK, FitzGerald GA (1985) Preparation and analysis of deuterium-labeled aspirin: application to pharmacokinetic studies. J Pharm Sci 74:188-192
14. Tsikas D, Tewes KS, Gutzki FM, Schwedhelm E, Greipel J, Frolich JC (1998) Gas chromatographic-tandem mass spectrometric determination of acetylsalicylic acid in human plasma after oral administration of low-dose aspirin and guaimesal. J Chromatogr B Biomed Sci Appl 709:79-88
15. Cromlish WA, Kennedy BP (1996) Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. Biochem Pharmacol 52:1777-1785
16. Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413-421
17. Chulada PC, Thompson MB, Mahler JF et al (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705-4708
18. Ulrich CM, Whitton J, Yu JH et al (2005) PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616-619
19. Ulrich CM, Bigler J, Sparks R et al (2004) Polymorphisms in PTGS1 (= COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 13:889-893
20. Liu W, Poole EM, Ulrich CM, Kulmacz RJ (2011) Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors. Pharmacogenomics J 11:337-347
21. Poole EM, Hsu L, Xiao L et al (2010) Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 19:547-557
22. Poole EM, Bigler J, Whitton J et al (2007) Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis 28:1259-1263
23. Slattery ML, Potter J, Caan B et al (1997) Energy balance and colon cancer - beyond physical activity. Cancer Res 57:75-80
24. Slattery ML, Caan BJ, Benson J, Murtaugh M (2003) Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr Cancer 46:166-171
25. Slattery ML, Edwards SL, Ma KN, Friedman GD, Potter JD (1997) Physical activity and colon cancer: a public health perspective. Ann Epidemiol 7:137-145
26. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S (1997) Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 8:146-158
27. Newcomb PA, Baron J, Cotterchio M et al (2007) Colon cancer family registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 16:2331-2343
28. Murtaugh MA, Ma KN, Benson J, Curtin K, Caan B, Slattery ML (2004) Antioxidants, carotenoids, and risk of rectal cancer. Am J Epidemiol 159:32-41
29. Slattery ML, Edwards S, Curtin K et al (2003) Physical activity and colorectal cancer. Am J Epidemiol 158:214-224
30. Slattery ML, Potter JD, Duncan DM, Berry TD (1997) Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Int J Cancer 73:670-677
31. Slattery ML, Levin TR, Ma K, Goldgar D, Holubkov R, Edwards S (2003) Family history and colorectal cancer: predictors of risk. Cancer Causes Control 14:879-887
32. Friedman GD, Coates AO, Potter JD, Slattery ML (1998) Drugs and colon cancer. Pharmacoepidemiol Drug Saf 7:99-106
33. Seufert BL, Poole EM, Whitton J, et al (2013) IkappaBKbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the colon cancer family registry. Carcinogenesis 34(1):79-85
34. Coghill AE, Newcomb PA, Campbell PT, et al (2011) Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 60(4):491-498
35. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106-120
36. Thorisson GA, Smith AV, Krishnan L, Stein LD (2005) The international HapMap project web site. Genome Res 15:1592-1593
37. Ulrich CM, Bigler J, Sibert J et al (2002) Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 20:409-410
38. Dudoit S, van der Laan MJ, Pollard KS (2004) Multiple testing. Part I. Single-step procedures for control of general type I error rates. Stat Appl Genet Mol Biol 3: Article13
39. Witte JS, Gauderman WJ, Thomas DC (1999) Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. Am J Epidemiol 149:693-705
40. Hamajima N, Takezaki T, Matsuo K et al (2001) Genotype frequencies of cyclooxygenase 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac J Cancer Prev 2:57-62
41. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, Gonzalez-Aguilera JJ, Fernandez-Peralta AM (2009) Effect of COX2-765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 20:1421-1429
42. Thompson CL, Plummer SJ, Merkulova A et al (2009) No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol 15:2240-2244
43. Cao H, Xu Z, Long H, Li XQ, Li SL (2010) The -765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis. Tohoku J Exp Med 222:15-21
44. Dong J, Dai J, Zhang M, Hu Z, Shen H (2010) Potentially functional COX-2-1195 G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 25:1042-1050
45. Zhu W, Wei BB, Shan X, Liu P (2010) 765 G>C and 8473 T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37:277-288
46. Pereira C, Medeiros RM, Dinis-Ribeiro MJ (2009) Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 21:76-91
47. Theodoratou E, Montazeri Z, Hawken S et al (2012) Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 104:1433-1457
48. Siemes C, Visser LE, Coebergh JW, Hofman A, Uitterlinden AG, Stricker BH (2008) Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr Cancer Drug Targets 8:753-764
49. Papafili A, Hill MR, Brull DJ et al (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22:1631-1636
50. Sanak M, Szczeklik W, Szczeklik A (2005) Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 116:221-223
51. Szczeklik W, Sanak M, Szczeklik A (2004) Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 114:248-253
52. Sanak M, Plutecka H, Szczeklik W, Piwowarska W, Rostoff P, Szczeklik A (2010) Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease. Pol Arch Med Wewn 120:82-88
53. Zheng J, Chen S, Jiang L, You Y, Wu D, Zhou Y. (2011) Functional Genetic Variations of Cyclooxygenase-2 and Susceptibility to Acute Myeloid Leukemia in a Chinese Population. Eur J Haematol 87(6):486-493
54. Lee CR, Bottone FG Jr, Krahn JM et al (2007) Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 17:145-160
55. Cross JT, Poole EM, Ulrich CM (2008) A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J 8:237-247